Enara Bio, Ltd. is a UK biotechnology company that discovers cancer targets, including tumor-specific antigens, using immunopeptidomics and machine-learning technologies. It works with biopharmaceutical companies to support development of cancer vaccines and other targeted immunotherapies.
Subscribe to see Enara Bio, Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Enara Bio, Ltd. is a biotech company. Xcout tracks 15 named people at Enara Bio, Ltd., including Kevin Pojasek (President and CEO). Xcout recorded 2 job postings from Enara Bio, Ltd. in the last 90 days.
9 more named people on record for Enara Bio, Ltd., with roles, board committees and tenure — see the full roster →
Xcout recorded 2 job postings from Enara Bio, Ltd. in the last 90 days, from a hiring record Xcout has kept since September 2026.
The weekly hiring trend, the roles and locations behind it — see Enara Bio, Ltd.'s hiring signals →
A few of Enara Bio, Ltd.'s closest competitors — see the full list of competitors and alternatives →
Noetik Inc. is an AI-native biotechnology company headquartered in South San Francisco, California, leveraging advanced machine learning methods for biological discovery.
Sift Biosciences is a privately held biotechnology company founded in 2024 and headquartered in San Carlos, California. The company is focused on harnessing pre-existing hidden immunity.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Gritstone bio, Inc. is a clinical-stage biotechnology company headquartered in Emeryville, California. The firm engages in developing next-generation cancer immunotherapies and vaccines to fight various forms of cancer and infectious diseases.
GATC Health Corp. is a biotechnology company that uses artificial intelligence, genomics, and toxicology data to discover and develop therapeutics and predict drug safety. Its work is aimed at pharmaceutical and biotechnology partners as well as patients needing treatments for serious diseases.
Epitopea is a transatlantic cancer immunotherapeutics company operating from Montreal, Canada, and Cambridge, United Kingdom. Backed by life-science investors, the company develops novel therapeutics utilizing its proprietary CryptoMap platform.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.